Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials

Find Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease) Clinical Trials Near You

GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The GB-PRIME Study is an early feasibility study designed to assess the clinical safety and functionality of the Neuralink N1 Implant and R1 Robot. This study involves participants who have tetraparesis, tetraplegia, or a diagnosis that may lead to these conditions. The N1 Implant is a wireless, rechargeable device mounted on the skull, connected to electrode threads that are inserted into the brain by the R1 Robot, which is a robotic device specifically designed for this procedure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• (a) A diagnosis of a spinal cord injury, brain stem stroke, or other neurological condition causing the participant to be non-ambulant and with bilateral upper limb motor impairment with no expectation of recovery that significantly or completely impairs the participant's ability to manually control a computer, smartphone or tablet with their hands.

⁃ OR (b) A diagnosis of Amyotrophic Lateral Sclerosis (ALS) or other progressive neurological condition where the natural history of the disease is well understood and where there is tetraparesis and the expectation in the view of the participants treating neurologist that the disease will progress such that the participant will meet 1a within 1 year of recruitment.

• Life expectancy ≥ 12 months.

• Ability to communicate in English

• Presence of a stable caregiver

Locations
Other Locations
United Kingdom
University College London Hospitals NHS Foundation Trust
RECRUITING
London
The Newcastle upon Tyne Hospitals NHS Foundation Trust
RECRUITING
Newcastle Upon Tyne
Contact Information
Primary
Neuralink Clinical Team
clinical-team-ct@neuralink.com
(877) 398-4465
Time Frame
Start Date: 2025-07-31
Estimated Completion Date: 2031-02
Participants
Target number of participants: 7
Treatments
Other: GB-PRIME: Precise Robotically Implanted Brain-Computer Interface
Open label
Sponsors
Collaborators: Newcastle-upon-Tyne Hospitals NHS Trust, University College London Hospitals
Leads: Neuralink Corp

This content was sourced from clinicaltrials.gov